New Clinical Data Confirms Soquelitinib’s Efficacy in Patients with Treatment-Resistant Atopic Dermatitis

Corvus Pharmaceuticals announces successful Phase 1 data for soquelitinib, showing significant skin improvement and safety for atopic dermatitis patients.